Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Correction: The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance.

Hepburn AC, Steele RE, Veeratterapillay R, Wilson L, Kounatidou EE, Barnard A, Berry P, Cassidy JR, Moad M, El-Sherif A, Gaughan L, Mills IG, Robson CN, Heer R.

Oncogene. 2019 May;38(22):4425. doi: 10.1038/s41388-019-0826-2.

PMID:
31068666
2.

Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.

Fletcher CE, Sulpice E, Combe S, Shibakawa A, Leach DA, Hamilton MP, Chrysostomou SL, Sharp A, Welti J, Yuan W, Dart DA, Knight E, Ning J, Francis JC, Kounatidou EE, Gaughan L, Swain A, Lupold SE, de Bono JS, McGuire SE, Gidrol X, Bevan CL.

Oncogene. 2019 May 1. doi: 10.1038/s41388-019-0823-5. [Epub ahead of print]

PMID:
31043708
3.

A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities.

Kounatidou E, Nakjang S, McCracken SRC, Dehm SM, Robson CN, Jones D, Gaughan L.

Nucleic Acids Res. 2019 Apr 22. pii: gkz286. doi: 10.1093/nar/gkz286. [Epub ahead of print]

PMID:
31006810
4.

The Pioneering Role of GATA2 in Androgen Receptor Variant Regulation Is Controlled by Bromodomain and Extraterminal Proteins in Castrate-Resistant Prostate Cancer.

Chaytor L, Simcock M, Nakjang S, Heath R, Walker L, Robson C, Jones D, Gaughan L.

Mol Cancer Res. 2019 Jun;17(6):1264-1278. doi: 10.1158/1541-7786.MCR-18-1231. Epub 2019 Mar 4.

PMID:
30833300
5.

The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance.

Hepburn AC, Steele RE, Veeratterapillay R, Wilson L, Kounatidou EE, Barnard A, Berry P, Cassidy JR, Moad M, El-Sherif A, Gaughan L, Mills IG, Robson CN, Heer R.

Oncogene. 2019 May;38(22):4412-4424. doi: 10.1038/s41388-019-0712-y. Epub 2019 Feb 11. Erratum in: Oncogene. 2019 May 8;:.

PMID:
30742096
6.

Food for thought. Malnutrition risk associated with increased risk of healthcare-associated infection.

Fitzpatrick F, Skally M, O'Hanlon C, Foley M, Houlihan J, Gaughan L, Smith O, Moore B, Cunneen S, Sweeney E, Dinesh B, O'Connell K, Smyth E, Humphreys H, Burns K.

J Hosp Infect. 2019 Mar;101(3):300-304. doi: 10.1016/j.jhin.2018.12.012. Epub 2018 Dec 25.

PMID:
30590089
7.

An interdisciplinary approach to improve surgical antimicrobial prophylaxis.

Conaty O, Gaughan L, Downey C, Carolan N, Brophy MJ, Kavanagh R, McNamara DAA, Smyth E, Burns K, Fitzpatrick F.

Int J Health Care Qual Assur. 2018 Mar 12;31(2):162-172. doi: 10.1108/IJHCQA-05-2017-0078.

PMID:
29504869
8.

Differential regulation of the androgen receptor by protein phosphatase regulatory subunits.

Grey J, Jones D, Wilson L, Nakjang S, Clayton J, Temperley R, Clark E, Gaughan L, Robson C.

Oncotarget. 2017 Dec 4;9(3):3922-3935. doi: 10.18632/oncotarget.22883. eCollection 2018 Jan 9.

9.

The methyltransferase SET9 regulates TGFB1 activation of renal fibroblasts via interaction with SMAD3.

Shuttleworth VG, Gaughan L, Nawafa L, Mooney CA, Cobb SL, Sheerin NS, Logan IR.

J Cell Sci. 2018 Jan 8;131(1). pii: jcs207761. doi: 10.1242/jcs.207761.

10.

The potential contribution of 16S ribosomal RNA polymerase chain reaction to antimicrobial stewardship in culture-negative infection.

O'Donnell S, Gaughan L, Skally M, Baker Z, O'Connell K, Smyth E, Fitzpatrick F, Humphreys H.

J Hosp Infect. 2018 Jun;99(2):148-152. doi: 10.1016/j.jhin.2017.08.016. Epub 2017 Aug 21.

PMID:
28838799
11.

Evaluation of fixed and variable hospital costs due to Clostridium difficile infection: institutional incentives and directions for future research.

Ryan P, Skally M, Duffy F, Farrelly M, Gaughan L, Flood P, McFadden E, Fitzpatrick F.

J Hosp Infect. 2017 Apr;95(4):415-420. doi: 10.1016/j.jhin.2017.01.016. Epub 2017 Feb 2.

PMID:
28320542
12.

The epidemiology of Clostridium difficile infection in a national kidney transplant center.

Kennedy C, Waldron C, Skally M, Gaughan L, Magee C, Burns K, Fitzpatrick F.

Clin Transplant. 2017 Jun;31(6). doi: 10.1111/ctr.12962. Epub 2017 Apr 12.

PMID:
28295646
13.

Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer.

Jones D, Noble M, Wedge SR, Robson CN, Gaughan L.

Sci Rep. 2017 Feb 16;7:40957. doi: 10.1038/srep40957.

14.

Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity.

McClurg UL, Cork DMW, Darby S, Ryan-Munden CA, Nakjang S, Mendes Côrtes L, Treumann A, Gaughan L, Robson CN.

Nucleic Acids Res. 2017 Feb 28;45(4):1793-1804. doi: 10.1093/nar/gkw1162.

15.

Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells.

Logan IR, McClurg UL, Jones DL, O'Neill DJ, Shaheen FS, Lunec J, Gaughan L, Robson CN.

Oncotarget. 2016 Nov 15;7(46):74724-74733. doi: 10.18632/oncotarget.12542.

16.

Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer.

McClurg UL, Harle VJ, Nabbi A, Batalha-Pereira A, Walker S, Coffey K, Gaughan L, McCracken SR, Robson CN.

Oncotarget. 2015 Nov 10;6(35):37724-36. doi: 10.18632/oncotarget.6075.

17.

FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.

Jones D, Wade M, Nakjang S, Chaytor L, Grey J, Robson CN, Gaughan L.

Oncotarget. 2015 Oct 6;6(30):29782-94. doi: 10.18632/oncotarget.4927.

18.

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.

O'Neill D, Jones D, Wade M, Grey J, Nakjang S, Guo W, Cork D, Davies BR, Wedge SR, Robson CN, Gaughan L.

Oncotarget. 2015 Sep 22;6(28):26029-40. doi: 10.18632/oncotarget.4347.

19.

The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer.

Wade MA, Jones D, Wilson L, Stockley J, Coffey K, Robson CN, Gaughan L.

Nucleic Acids Res. 2015 Jan;43(1):196-207. doi: 10.1093/nar/gku1298. Epub 2014 Dec 8.

20.

AGE-modified basement membrane cooperates with Endo180 to promote epithelial cell invasiveness and decrease prostate cancer survival.

Rodriguez-Teja M, Gronau JH, Breit C, Zhang YZ, Minamidate A, Caley MP, McCarthy A, Cox TR, Erler JT, Gaughan L, Darby S, Robson C, Mauri F, Waxman J, Sturge J.

J Pathol. 2015 Mar;235(4):581-92. doi: 10.1002/path.4485. Epub 2014 Dec 24.

PMID:
25408555
21.

Survival Outcome and EMT Suppression Mediated by a Lectin Domain Interaction of Endo180 and CD147.

Rodriguez-Teja M, Gronau JH, Minamidate A, Darby S, Gaughan L, Robson C, Mauri F, Waxman J, Sturge J.

Mol Cancer Res. 2015 Mar;13(3):538-47. doi: 10.1158/1541-7786.MCR-14-0344-T. Epub 2014 Nov 7.

22.

The co-chaperone p23 promotes prostate cancer motility and metastasis.

Cano LQ, Lavery DN, Sin S, Spanjaard E, Brooke GN, Tilman JD, Abroaf A, Gaughan L, Robson CN, Heer R, Mauri F, de Rooij J, Driouch K, Bevan CL.

Mol Oncol. 2015 Jan;9(1):295-308. doi: 10.1016/j.molonc.2014.08.014. Epub 2014 Sep 6.

23.

Deubiquitinating enzyme Usp12 regulates the interaction between the androgen receptor and the Akt pathway.

McClurg UL, Summerscales EE, Harle VJ, Gaughan L, Robson CN.

Oncotarget. 2014 Aug 30;5(16):7081-92.

24.

SETD6 controls the expression of estrogen-responsive genes and proliferation of breast carcinoma cells.

O'Neill DJ, Williamson SC, Alkharaif D, Monteiro IC, Goudreault M, Gaughan L, Robson CN, Gingras AC, Binda O.

Epigenetics. 2014 Jul;9(7):942-50. doi: 10.4161/epi.28864. Epub 2014 Apr 21.

25.

Deubiquitinating enzyme Usp12 is a novel co-activator of the androgen receptor.

Burska UL, Harle VJ, Coffey K, Darby S, Ramsey H, O'Neill D, Logan IR, Gaughan L, Robson CN.

J Biol Chem. 2013 Nov 8;288(45):32641-50. doi: 10.1074/jbc.M113.485912. Epub 2013 Sep 21.

26.

AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.

Loddick SA, Ross SJ, Thomason AG, Robinson DM, Walker GE, Dunkley TP, Brave SR, Broadbent N, Stratton NC, Trueman D, Mouchet E, Shaheen FS, Jacobs VN, Cumberbatch M, Wilson J, Jones RD, Bradbury RH, Rabow A, Gaughan L, Womack C, Barry ST, Robson CN, Critchlow SE, Wedge SR, Brooks AN.

Mol Cancer Ther. 2013 Sep;12(9):1715-27. doi: 10.1158/1535-7163.MCT-12-1174. Epub 2013 Jul 16.

27.

KDM4B is a master regulator of the estrogen receptor signalling cascade.

Gaughan L, Stockley J, Coffey K, O'Neill D, Jones DL, Wade M, Wright J, Moore M, Tse S, Rogerson L, Robson CN.

Nucleic Acids Res. 2013 Aug;41(14):6892-904. doi: 10.1093/nar/gkt469. Epub 2013 May 30.

28.

The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover.

Coffey K, Rogerson L, Ryan-Munden C, Alkharaif D, Stockley J, Heer R, Sahadevan K, O'Neill D, Jones D, Darby S, Staller P, Mantilla A, Gaughan L, Robson CN.

Nucleic Acids Res. 2013 Apr;41(8):4433-46. doi: 10.1093/nar/gkt106. Epub 2013 Feb 21.

29.

Tartrazine and sunset yellow are xenoestrogens in a new screening assay to identify modulators of human oestrogen receptor transcriptional activity.

Axon A, May FE, Gaughan LE, Williams FM, Blain PG, Wright MC.

Toxicology. 2012 Aug 16;298(1-3):40-51. doi: 10.1016/j.tox.2012.04.014. Epub 2012 May 3.

PMID:
22562034
30.

Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome.

Rajan P, Dalgliesh C, Carling PJ, Buist T, Zhang C, Grellscheid SN, Armstrong K, Stockley J, Simillion C, Gaughan L, Kalna G, Zhang MQ, Robson CN, Leung HY, Elliott DJ.

PLoS One. 2011;6(12):e29088. doi: 10.1371/journal.pone.0029088. Epub 2011 Dec 14.

31.

Targeting the DNA double strand break repair machinery in prostate cancer.

Shaheen FS, Znojek P, Fisher A, Webster M, Plummer R, Gaughan L, Smith GC, Leung HY, Curtin NJ, Robson CN.

PLoS One. 2011;6(5):e20311. doi: 10.1371/journal.pone.0020311. Epub 2011 May 23.

32.

FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth.

Brooke GN, Culley RL, Dart DA, Mann DJ, Gaughan L, McCracken SR, Robson CN, Spencer-Dene B, Gamble SC, Powell SM, Wait R, Waxman J, Walker MM, Bevan CL.

Cancer Res. 2011 Feb 1;71(3):914-24. doi: 10.1158/0008-5472.CAN-10-0874. Epub 2010 Dec 17.

33.

Regulation of the androgen receptor by SET9-mediated methylation.

Gaughan L, Stockley J, Wang N, McCracken SR, Treumann A, Armstrong K, Shaheen F, Watt K, McEwan IJ, Wang C, Pestell RG, Robson CN.

Nucleic Acids Res. 2011 Mar;39(4):1266-79. doi: 10.1093/nar/gkq861. Epub 2010 Oct 19. Erratum in: Nucleic Acids Res. 2013 Jul;41(13):6783.

34.

The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer.

Clark EL, Coulson A, Dalgliesh C, Rajan P, Nicol SM, Fleming S, Heer R, Gaughan L, Leung HY, Elliott DJ, Fuller-Pace FV, Robson CN.

Cancer Res. 2008 Oct 1;68(19):7938-46. doi: 10.1158/0008-5472.CAN-08-0932.

35.

Regulation of gene expression by the RNA-binding protein Sam68 in cancer.

Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, Elliott DJ.

Biochem Soc Trans. 2008 Jun;36(Pt 3):505-7. doi: 10.1042/BST0360505. Review.

PMID:
18481990
36.

The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor.

Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, Elliott DJ.

J Pathol. 2008 May;215(1):67-77. doi: 10.1002/path.2324.

PMID:
18273831
37.

Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.

Logan IR, Gaughan L, McCracken SR, Sapountzi V, Leung HY, Robson CN.

Mol Cell Biol. 2006 Sep;26(17):6502-10.

38.

Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors.

Mills IG, Gaughan L, Robson C, Ross T, McCracken S, Kelly J, Neal DE.

J Cell Biol. 2005 Jul 18;170(2):191-200.

39.

A human T-cell lymphotropic virus type 1 enhancer of Myc transforming potential stabilizes Myc-TIP60 transcriptional interactions.

Awasthi S, Sharma A, Wong K, Zhang J, Matlock EF, Rogers L, Motloch P, Takemoto S, Taguchi H, Cole MD, Lüscher B, Dittrich O, Tagami H, Nakatani Y, McGee M, Girard AM, Gaughan L, Robson CN, Monnat RJ Jr, Harrod R.

Mol Cell Biol. 2005 Jul;25(14):6178-98.

40.

Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation.

Gaughan L, Logan IR, Neal DE, Robson CN.

Nucleic Acids Res. 2005 Jan 7;33(1):13-26. Print 2005.

41.

Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.

Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN.

Prostate. 2004 May 1;59(2):177-89.

PMID:
15042618
42.

Control of human PIRH2 protein stability: involvement of TIP60 and the proteosome.

Logan IR, Sapountzi V, Gaughan L, Neal DE, Robson CN.

J Biol Chem. 2004 Mar 19;279(12):11696-704. Epub 2003 Dec 29.

43.

Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor.

Gaughan L, Logan IR, Cook S, Neal DE, Robson CN.

J Biol Chem. 2002 Jul 19;277(29):25904-13. Epub 2002 May 6.

44.

Tip60 is a co-activator specific for class I nuclear hormone receptors.

Gaughan L, Brady ME, Cook S, Neal DE, Robson CN.

J Biol Chem. 2001 Dec 14;276(50):46841-8. Epub 2001 Oct 8.

45.

Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin.

Ozanne DM, Brady ME, Cook S, Gaughan L, Neal DE, Robson CN.

Mol Endocrinol. 2000 Oct;14(10):1618-26.

PMID:
11043577
46.

Tip60 is a nuclear hormone receptor coactivator.

Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, Neal DE, Robson CN.

J Biol Chem. 1999 Jun 18;274(25):17599-604.

47.

Identification of patient-controlled analgesia overdoses in hospitalized patients: a computerized method of monitoring adverse events.

Whipple JK, Quebbeman EJ, Lewis KS, Gaughan LM, Gallup EL, Ausman RK.

Ann Pharmacother. 1994 May;28(5):655-8.

PMID:
8069006
48.

Distribution and metabolic fate of trans- and cis-permethrin in laying hens.

Gaughan LC, Robinson RA, Casida JE.

J Agric Food Chem. 1978 Nov-Dec;26(6):1374-80. No abstract available.

PMID:
730949
49.

The right of a mental patient to refuse antipsychotic drugs in an institution.

Gaughan LD, LaRue LH.

Law Psychol Rev. 1978 Fall;4:43-85. No abstract available.

PMID:
11662727
50.

Distribution and metabolism of trans- and cis-permethrin in lactating Jersey cows.

Gaughan LC, Ackerman ME, Unai T, Casida JE.

J Agric Food Chem. 1978 May-Jun;26(3):613-8. No abstract available.

PMID:
566284

Supplemental Content

Loading ...
Support Center